Profile data is unavailable for this security.
About the company
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
- Revenue in USD (TTM)17.50m
- Net income in USD-58.88m
- Incorporated2019
- Employees42.00
- LocationLENZ Therapeutics Inc201 Lomas Santa Fe Drive, Suite 300SOLANA BEACH 92075United StatesUSA
- Phone+1 (858) 925-7000
- Fax+1 (302) 655-5049
- Websitehttps://lenz-tx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 394.40m | 25.00 | -- | -- | -- | 420.92 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| Benitec Biopharma Inc | 0.00 | -41.82m | 394.49m | 19.00 | -- | 3.27 | -- | -- | -1.18 | -1.18 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -50.76 | -79.73 | -52.87 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 396.88m | 16.00 | -- | 2.80 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 407.81m | 104.00 | 21.03 | 5.76 | 19.23 | 3.27 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 411.95m | 51.00 | -- | 1.54 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 414.59m | 70.00 | -- | 18.81 | -- | 38.33 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 422.73m | 42.00 | -- | -- | -- | 24.16 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Entrada Therapeutics Inc | 61.52m | -103.46m | 423.09m | 183.00 | -- | 1.24 | -- | 6.88 | -2.50 | -2.50 | 1.47 | 8.91 | 0.1272 | -- | 32.39 | 336,174.90 | -21.39 | -8.44 | -23.70 | -10.02 | -- | -- | -168.16 | -33.36 | -- | -- | 0.00 | -- | 63.38 | -- | 1,081.69 | -- | 38.04 | -- |
| Regenxbio Inc | 161.32m | -177.92m | 430.30m | 353.00 | -- | 2.66 | -- | 2.67 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 431.31m | 129.00 | -- | 2.18 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 432.24m | 27.00 | -- | 8.37 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 432.76m | 73.00 | -- | 2.37 | -- | 11.64 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| Vanda Pharmaceuticals Inc. | 212.07m | -84.20m | 439.09m | 368.00 | -- | 0.9422 | -- | 2.07 | -1.43 | -1.43 | 3.61 | 7.89 | 0.3403 | 6.46 | 4.55 | 576,288.10 | -13.51 | 1.56 | -16.20 | 1.80 | 94.44 | 91.45 | -39.70 | 3.99 | 3.10 | -- | 0.011 | 0.00 | 3.18 | -2.64 | -853.29 | -- | -13.62 | -- |
Data as of Feb 12 2026. Currency figures normalised to LENZ Therapeutics Inc's reporting currency: US Dollar USD
57.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 05 Nov 2025 | 4.24m | 13.55% |
| Alpha Wave Global LPas of 30 Sep 2025 | 3.61m | 11.54% |
| Ridgeback Capital Management LLCas of 14 Apr 2025 | 1.95m | 6.24% |
| UBS Securities LLCas of 31 Dec 2025 | 1.57m | 5.02% |
| Point72 Asset Management LPas of 30 Sep 2025 | 1.36m | 4.34% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.32m | 4.22% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.16m | 3.70% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 1.07m | 3.43% |
| Tang Capital Management LLCas of 30 Sep 2025 | 897.62k | 2.87% |
| RTW Investments LPas of 30 Sep 2025 | 863.39k | 2.76% |
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
